Show simple item record

dc.contributor.authorRaninga, PV
dc.contributor.authorDi Trapani, G
dc.contributor.authorTonissen, KF
dc.date.accessioned2017-05-03T13:22:23Z
dc.date.available2017-05-03T13:22:23Z
dc.date.issued2014
dc.date.modified2014-08-08T04:01:39Z
dc.identifier.issn2331-4737
dc.identifier.urihttp://hdl.handle.net/10072/62015
dc.description.abstractOxidative stress, which is associated with an increased concentration of reactive oxygen species (ROS), is involved in the pathogenesis of numerous diseases including cancer. In response to increased ROS levels, cellular antioxidant molecules such as thioredoxin, peroxiredoxins, glutaredoxins, DJ-1, and superoxide dismutases are upregulated to counteract the detrimental effect of ROS. However, cancer cells take advantage of upregulated antioxidant molecules for protection against ROS- induced cell damage. This review focuses on two antioxidant systems, Thioredoxin and DJ-1, which are upregulated in many human cancer types, correlating with tumour proliferation, survival, and chemo-resistance. Thus, both of these antioxidant molecules serve as potential molecular targets to treat cancer. However, targeting one of these antioxidants alone may not be an effective anti-cancer therapy. Both of these antioxidant molecules are interlinked and act on similar downstream targets such as NF-?߬ PTEN, and Nrf2 to exert cytoprotection. Inhibiting either thioredoxin or DJ-1 alone may allow the other antioxidant to activate downstream signalling cascades leading to tumour cell survival and proliferation. Targeting both thioredoxin and DJ-1 in conjunction may completely shut down the antioxidant defence system regulated by these molecules. This review focuses on the cross-talk between thioredoxin and DJ-1 and highlights the importance and consequences of targeting thioredoxin and DJ-1 together to develop an effective anti-cancer therapeutic strategy.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent503221 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoeng
dc.publisherImpact Journals LLC
dc.publisher.placeUnited States
dc.publisher.urihttp://www.impactjournals.com/oncoscience/index.php?abs=12
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom95
dc.relation.ispartofpageto110
dc.relation.ispartofissue1
dc.relation.ispartofjournalOncoscience
dc.relation.ispartofvolume1
dc.rights.retentionY
dc.subject.fieldofresearchBiochemistry and cell biology not elsewhere classified
dc.subject.fieldofresearchCancer cell biology
dc.subject.fieldofresearchcode310199
dc.subject.fieldofresearchcode321101
dc.titleCross Talk between Two Antioxidant Systems, Thioredoxin and DJ-1: Consequences for Cancer
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/by/3.0/
gro.facultyGriffith Sciences, Griffith Institute for Drug Discovery
gro.rights.copyright© The Author(s) 2014. This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorDi Trapani, Jenny
gro.griffith.authorTonissen, Kathryn F.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record